Biomarkers obtained by non-invasive methods in patients with COPD: Where do we stand, what do we expect?

Current Medicinal Chemistry

Volumn 16, Issue 22, 2009, Pages 2824-2838

  Hillas, Georgios ^a   Loukides, Stelios ^a,c   Kostikas, Konstantinos ^b   Bakakos, Petros ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c NONE   (Greece)

Author keywords

Biomarkers; COPD; Exhaled breath; Exhaled breath condensate; Fraction of exhaled nitric oxide; Sputum induction

Indexed keywords

8 ISOPROSTANE; AMINOGUANIDINE; ARGININE; BIOLOGICAL MARKER; CARBON DIOXIDE; CORTICOSTEROID; GELATINASE B; GLUCOCORTICOID; HISTONE DEACETYLASE; HYDROGEN PEROXIDE; INTERLEUKIN 1BETA; LEUKOCYTE ELASTASE; LEUKOTRIENE B4; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; SALBUTAMOL; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; EXPIRATORY FLOW RATE; EXPIRED AIR; HUMAN; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; PH; REVIEW; SMOKING; SPUTUM ANALYSIS; SPUTUM CULTURE; SUPERNATANT;

BIOLOGICAL MARKERS; BREATH TESTS; HUMANS; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 70349379973     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803178     Document Type: Review

References (190)

1. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
2. Cazzola, M.; MacNee, W.; Martinez, F.J.; Rabe, K.F.; Franciosi, LG.; Barnes, P.J.; Brusasco, V.; Burge, P.S.; Calverley, P.M.; Celli, BR.; Jones, P.W.; Mahler, D.A.; Make, B.; Miravitlles, M.; Page, C.P.; Palange, P.; Parr, D.; Pistolesi, M.; Rennard, S.I.; Rutten-van Molken, M.P.; Stockley, R.; Sullivan, S.D.; Wedzicha, J.A.; Wouters, E.F. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur. Respir. J., 2008, 31, 416-69.
3. Rabe, K.F.; Hurd, S.; Anzueto, A.; Barnes, P.J.; Buist, S.A.; Calverley, P.; Fukuchi, Y.; Jenkins, C.; Rodriguez-Roisin, R.; van Weel, C.; Zielinski, J. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med., 2007, 176, 532-55.
4. Snell, N.; Newbold, P. The clinical utility of biomarkers in asthma and COPD. Curr. Opin. Pharmacol., 2008, 8, 222-35.
5. Brightling, C.E. Clinical applications of induced sputum. Chest, 2006, 129, 1344-48.
6. Kharitonov, S.A.; Barnes, P.J. Exhaled biomarkers. Chest, 2006, 130, 1541-46.
7. ATS Workshop proceedings: Exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate. Proc. Am. Thorac. Soc., 2006, 3, 131-45.
8. Brindicci, C.; Ito, K.; Resta, O.; Pride, N.B.; Barnes, P.J.; Kharitonov, S.A. Exhaled nitric oxide from lung periphery is increased in COPD. Eur. Respir. J., 2005, 26, 52-9.
9. Horváth, I.; Hunt, J.; Barnes, P.J.; Alving, K.; Antczak, A.; Baraldi, E.; Becher, G.; van Beurden, W.J.; Corradi, M.; Dekhuijzen, R.; Dweik, R.A.; Dwyer, T.; Effros, R.; Erzurum, S.; Gaston, B.; Gessner, C.; Greening, A.; Ho, L.P.; Hohlfeld, J.; Jöbsis, Q.; Laskowski, D.; Loukides, S.; Marlin, D.; Montuschi, P.; Olin, AC.; Redington, A.E.; Reinhold, P.; van Rensen, E.L.; Rubinstein, I.; Silkoff, P.; Toren, K.; Vass, G.; Vogelberg, C.; Wirtz, H. ATS/ERS Task Force on Exhaled Breath Condensate Exhaled breath condensate: Methodological recommendations and unresolved questions. Eur. Respir. J., 2005, 26, 523-48.
10. Koutsokera, A.; Loukides, S.; Gourgoulianis, K.I.; Kostikas K. Biomarkers in the exhaled breath condensate of healthy adults: Mapping the path towards reference values. Curr. Med. Chem., 2008, 15, 620-30.
11. Pizzichini, E.; Pizzichini, M.M.; Leigh, R.; Djukanovi.., R.; Sterk, P.J. Safety of sputum induction. Eur. Respir. J., 2002, 20, 9-18.
12. Efthimiadis, A.; Spanevello, A.; Hamid, Q.; Kelly, M.M.; Linden, M.; Louis, R.; Pizzichini, M.M.; Pizzichini, E.; Ronchi, C.; Van Overvel, F.; Djukanović, R. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur. Respir. J., 2002, 20, 19-23.
13. Pin, I.; Gibson, P.G.; Kolendowicz, R.; Girgis-Gabardo, A.; Denburg, J.A.; Hargreave, F.E.; Dolovich, J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax, 1992, 47, 25-29.
14. Djukanovic, R.; Sterk, P.J.; Fahy, J.V.; Hargreave, FE. European Respiratory Society Task Force. Standardised methodology of sputum induction and processing. Eur. Respir. J., 2002, 20, 1-55.
15. Vignola, AM.; Rennard, S.I.; Hargreave, F.E.; Fahy, J.V.; Bonsignore, M.R.; Djukanovic, R.; Sterk, P.J. European Respiratory Society Task Force. Standardised methodology of sputum induction and processing: future directions. Report of Working Group 8. Eur. Respir. J., 2002, 20, 51-55.
16. Fahy, J.V.; Liu, J.; Wong, H.; Boushey, H.A. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev. Respir. Dis., 1993, 147, 1126-1131.
17. Richter, K.; Jörres, R.A.; Mucke, M.; Magnussen, H. Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1997, 155, A821.
18. Pizzichini, E.; Pizzichini, M.M.; Efthimiadis, A.; Hargreave, F.E.; Dolovich, J. Measurement of inflammatory indices in induced sputum: effects of Selection of sputum to minimize salivary contamination. Eur. Respir. J. 1996, 9, 1174-1180.
19. Cleland, W.W. Dithiothreitol, a new protective reagent for SH groups. Biochemistry, 1964, 3, 480-482.
20. Spanevello, A.; Beghe, B.; Bianchi, A.; Migliori, G.B.; Ambrosetti, M.; Neri. M.; Ind, P.W. Comparison of two methods of processing induced sputum: Selected versus entire sputum. Am. J. Respir. Crit. Care Med., 1998, 157, 665-668.
21. Efthimiadis, A.; Popov, T.; Kolendowicz, R.; Dolovich, J.; Hargreave, F.E. Increasing the yield of sputum cells for examination. Am. J. Respir. Crit. Care Med., 1994, 149, A149.
22. Rerecich, T.J.; Gauvreau, G.M.; Kelly, M.M.; Hargreave, F.E.; O'Byrne, P.M. Optimization of sputum fluid phase measurements. Am. J. Respir. Crit. Care Med., 1999, 159, A849.
23. Efthimiadis, A.; Hussack, P.; Weston, S.; Carruthers, S.; Hargreave, F.E. Induced sputum: Effect of centrifugation on the total and differential cell counts. Eur. Respir. J., 2000, 16, 251.
24. Louis, R.; Shute, J.; Goldring, K.; Perks, B.; Lau, LC.; Radermecker, M.; Djukanovic, R. The effect of processing on inflammatory markers in induced sputum. Eur. Respir. J., 1999, 13, 660-667.
25. Fleury-Feith, J.; Escudier, E.; Pocholle, M.J.; Carre, C.; Bernaudin, J.F. The effects of cytocentrifugation on differential cell counts in samples obtained by bronchoalveolar lavage. Acta Cytol., 1987, 31, 606-610.
26. Mordelet-Dambrine, M.; Arnoux, A.; Stanislas-Leguern, G.; Sandron, D.; Chretien, J.; Huchon, G. Processing of lung lavage fluid causes variability in Bronchoalveolar cell count. Am. Rev. Respir. Dis., 1984, 130, 305-306.
27. Pizzichini, M.M.; Popov, T.A.; Efthimiadis, A.; Hussack, P.; Evans, S.; Pizzichini, E.; Dolovich, J.; Hargreave, F.E. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am. J. Respir. Crit. Care Med., 1996, 154, 866-869.
28. Barnes, P.J.; Chowdhury, B.; Kharitonov, S.A.; Magnussen, H.; Page, C.P.; Postma, D.; Saetta, M. Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med., 2006, 174, 6-14.
29. Tsoumakidou, M.; Tzanakis, N.; Siafakas, N.M. Induced sputum in the investigation of airway inflammation of COPD. Respir. Med., 2003, 97, 863-871.
30. Bhowmik, A.; Seemungal, T.A.; Sapsford, R.J.; Devalia, J.L.; Wedzicha, J.A. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax, 1998, 53, 953-956.
31. Keatings, V.M.; Jatakanon, A.; Worsdell, Y.M.; Barnes, P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med., 1997, 155, 542-548.
32. Culpitt, S.V.; Nightingale, J.A.; Barnes, P.J. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1999, 160, 1635-1639.
33. Loppow, D.; Schleiss, M.B.; Kanniess, F.; Taube, C.; Jorres, R.A.; Magnussen, H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir. Med., 2001, 95, 115-121.
34. Keatings, V.M.; Collins, P.D.; Scott, D.M.; Barnes, P.J. Differences in interleukin-8 and tumor necrosis factor-.. in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med., 1996, 153, 530-534.
35. Yamamoto, C.; Yoneda, T.; Yoshikawa, M.; Fu, A.; Tokuyama, T.; Tsukaguchi, K.; Narita, N. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest, 1997, 112, 505-510.
36. Aaron, S.D.; Angel, J.B.; Lunau, M.; Wright, K.; Fex, C.; Le Saux, N.; Dales, RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2001, 163, 349-355.
37. Vernooy, J.H.; Kucukaycan, M.; Jacobs, J.A.; Chavannes, N.H.; Buurman, W.A.; Dentener, M.A.; Wouters, E.F. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: Soluble tumor necrosis factor receptors are increased in sputum. Am. J. Respir. Crit. Care Med., 2002, 166, 1218-1224.
38. Hacievliyagil, S.S.; Gunen, H.; Mutlu, L.C.; Karabulut, A.B.; Temel I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir. Med., 2006, 100, 846-854.
39. Broekhuizen, R.; Vernooy, JH.; Schols, A.M.; Dentener, M.A.; Wouters, E.F. Leptin as local inflammatory marker in COPD. Respir. Med., 2005, 99, 70-74.
40. Beeh, K.M.; Beier, J.; Kornmann, O.; Buhl, R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir. Med., 2003, 97, 634-639.
41. Vernooy, J.H.; Lindeman, J.H.; Jacobs, J.A.; Hanemaaijer, R.; Wouters, E.F. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest, 2004, 126, 1802-1810.
42. Culpitt, S.V.; Rogers, D.F.; Traves, S.L.; Barnes, P.J.; Donnelly, L.E. Sputum matrix metalloproteases: Comparison between chronic obstructive pulmonary disease and asthma. Respir. Med., 2005, 99, 703-710.
43. Demedts, I.K.; Morel-Montero, A.; Lebecque, S.; Pacheco, Y.; Cataldo, D.; Joos, G.F.; Pauwels, R.A.; Brusselle, G.G. Elevated MMP-12 protein levels in induced sputum from COPD patients. Thorax, 2006, 61, 196-201.
44. Hill, A.T.; Bayley, D.; Stockley, R.A. The interrelationship of sputum Inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med., 1999, 160, 893-898.
45. Dentener, M.A.; Vernooy, J.H.; Hendriks, S.; Wouters, E.F. Enhanced levels of hyaluronan in lungs of patients with COPD: Relationship with lung function and local inflammation. Thorax, 2005, 60, 114-119.
46. Boschetto, P.; Miotto, D.; Bononi, I.; Faggian, D.; Plebani, M.; Papi, A.; Creminon, C.; De Rosa, E.; Fabbri, L.M.; Mapp, C.E. Sputum substance P and neurokininAare reduced during exacerbations of chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther., 2005, 18, 199-205.
47. Woolhouse, I.S.; Bayley, D.L.; Stockley, R.A. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax, 2002, 57, 667-671.
48. Kelly, M.M.; Leigh, R.; Horsewood, P.; Gleich, G.J.; Cox, G.; Hargreave, F.E. Induced sputum: Validity of fluid-phase IL-5 measurement. J. Allergy Clin. Immunol., 2000, 105, 1162-1168.
49. Kelly, M.M.; Leigh, R.; Carruthers, S.; Horsewood, P.; Gleich, G.J.; Hargreave, F.E. Cox, G. Increased detection of interleukin-5 in sputum by addition of protease inhibitors. Eur. Respir. J., 2001, 18, 685-691.
50. Erin, E.M.; Jenkins, G.R.; Kon, O.M.; Zacharasiewicz, A.S.; Nicholson, G.C.; Neighbour, H.; Tennant, R.C.; Tan, A.J.; Leaker, B.R.; Bush, A.; Jose, P.J.; Barnes, P.J.; Hansel, T.T. Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants. Am. J. Respir. Crit. Care Med., 2008, 177, 132-141.
51. Stanescu, D.; Sanna, A.; Veriter, C.; Kostianev, S.; Calcagni, P.G.; Fabbri, L.M.; Maestrelli, P. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax, 1996, 51, 267-271.
52. Brightling, C.E.; Monteiro, W.; Ward, R.; Parker, D.; Morgan, M.D.; Wardlaw, A.J.; Pavord, I.D. Sputum eosinophilia and short-term response to Prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet, 2000, 356, 1480- 485.
53. Brightling, C.E.; McKenna, S.; Hargadon, B.; Birring, S.; Green, R.; Siva, R.; Berry, M.; Parker, D.; Monteiro, W.; Pavord, I.D.; Bradding, P. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax, 2005, 60, 193-198.
54. Tzanakis, N.; Chrysofakis, G.; Tsoumakidou, M.; Kyriakou, D.; Tsiligianni, J.; Bouros, D.; Siafakas, N.M. Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir. Med., 2004, 98, 57-65.
55. Pizzichini, E.; Pizzichini, M.M.; Gibson, P.; Parameswaran, K.; Gleich, G.J.; Berman, L.; Dolovich, J.; Hargreave, F.E. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med., 1998, 158(5 pt 1), 1511-1517
56. Siva, R.; Green, R.H.; Brightling, C.E. Modulation of eosinophilic inflammation in COPD. Eur. Respir. J., 2005, 26, 441.
57. Gustafsson, L.E.; Leone, A.M.; Persson, M.G.; Wiklund, N.P.; Moncada, S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun., 1991, 181, 852-857.
58. Lundberg, J.O.; Weitzberg, E.; Nordvall, S.L.; Kuylenstierna, R.; Lundberg, J.M.; Alving, K. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur. Respir. J., 1994, 7, 1501-1504.
59. Kharitonov, S.A.; Chung, K.F.; Evans, D.; O'Connor, B.J.; Barnes, P.J. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am. J. Respir. Crit. Care Med., 1996, 153, 1773-1780.
60. Silkoff, P.E.; McClean, P.A.; Caramori, M.; Slutsky, A.S.; Zamel, N. A significant proportion of exhaled nitric oxide arises in large airways in normal subjects. Respir. Physiol., 1998, 113, 33-38.
61. Tsujino, I.; Miyamoto, K.; Nishimura, M.; Shinano, H.; Makita, H.; Saito, S.; Nakano, T.; Kawakami, Y. Production of nitric oxide (NO) in intrathoracic airways of normal humans. Am. J. Respir. Crit. Care Med., 1996, 154, 1370-1374.
62. Byrnes, C.A.; Dinarevic, S.; Busst, C.; Bush, A.; Shinebourne, E.A. Is nitric oxide in exhaled air produced at airway or alveolar level? Eur. Respir. J., 1997, 10, 1021-1025.
63. Zetterquist, W.; Pedroletti, C.; Lundberg, J.O.; Alving, K. Salivary contribution to exhaled nitric oxide. Eur. Respir. J., 1999, 13, 327-333.
64. Ricciardolo, F.L.; Sterk, P.J.; Gaston, B.; Folkerts, G. Nitric oxide in health and disease of the respiratory system. Physiol. Rev., 2004, 84, 731-765.
65. Fostermann, U.; Schmidt, H.H.; Pollock, J.S.; Sheng, H.; Mitchell, J.A.; Warner, T.D.; Nakane, M.; Murad, F. Isoforms of nitric oxide synthase: characterization and purification from different cell types. Biochem. Pharmacol., 1991, 42, 1849-1857.
66. Belvisi, M.G.; Stretton, C.D.; Yacoub, M.; Barnes, P.J. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur. J. Pharmacol., 1992, 210, 221-222.
67. Li, C.G.; Rand, M.J. Evidence that part of the NANC relaxant response of guinea pig trachea to electrical field stimulation is mediated by nitric oxide. Br. J. Pharmacol., 1991, 102, 91-94.
68. Li, D.; Shirakami, G.; Zhan, X.; Johns, RA. Regulation of ciliary beat frequency by the nitric oxide cyclic guanosine monophosphate signaling pathway in rat airway epithelial cells. Am. J. Respir. Cell Mol. Biol., 2000, 23, 175-181.
69. Getsberg, I.; Hellman, V.; Fainshtein, M.; Weil, S.; Silberberg, S.D.; Danilenko, M.; Priel, Z. Intracellular Ca2+ regulates the phosphorylation and the dephosphorylation of ciliary proteins via the NO pathway. J. Gen. Physiol., 2004, 124, 527-540.
70. Radomski, M.W.; Palmer, R.M.J.; Moncada, S. Glucocorticoids inhibit the expresssion of an inducible, but not the constitutive nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA, 1990, 87, 10043-10047.
71. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med., 1993, 329, 2002-2012.
72. Dweik, R.A.; Laskowski, D.; Abu-Soud, H.M.; Kaneko, F.; Hutte, R.; Stuehr, D.J.; Erzurum, S.C. Nitric oxide synthesis in the lung: regulation by oxygen through a kinetic mechanism. J. Clin. Invest., 1998, 101, 660-666.
73. Deykin, A.; Massaro, A.F.; Drazen, J.M.; Israel, E. Exhaled nitric oxide as a diagnostic test for asthma: Online versus offline techniques and effect of flow rate. Am. J. Respir. Crit. Care Med., 2002, 165, 1597-1601.
74. Silkoff, P.E.; McClean, P.A.; Slutsky, A.S.; Furlott, H.G.; Hoffstein, E.; Wakita, S,; Chapman, K.R.; Szalai, J.P.; Zamel, N. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am. J. Respir. Crit. Care Med., 1997, 155, 260-267.
75. Franklin, P.J.; Taplin, R.; Stick, S.M. A community study of exhaled nitric oxide in healthy children. Am. J. Respir. Crit. Care Med., 1999, 159, 69-73.
76. Kissoon, N.; Duckworth, L.J.; Blake, K.V.; Murphy, S.P.; Taylor, C.L.; Silkoff, P.E. FE(NO): Relationship to exhalation rates and online versus bag collection in healthy adolescents. Am. J. Respir. Crit. Care Med., 2000, 162, 539-545.
77. Kissoon, N.; Duckworth, L.J.; Blake, K.V.; Murphy, S.P.; Taylor, C.L.; DeNicola, L.R.; Silkoff, P.E. Exhaled nitric oxide concentrations: online versus offline values in healthy children. Pediatr. Pulmonol., 2002, 33, 283-292.
78. Olin, A.C.; Rosengren, A.; Thelle, D.S.; Lissner, L.; Bake, B.; Torén, K. Height, age and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest, 2006, 130, 1319-1325.
79. Tsang, K.W.; Ip, S.K.; Leung, R.; Tipoe, G.L.; Chan, S.L.; Shum, I.H.; Ip, M.S.; Yan, C.; Fung, P.C.; Chan-Yeung, M.; Lam, W. Exhaled nitric oxide: The effects of age, gender and body size. Lung, 2001, 179, 83-91.
80. Deykin, A.; Halpern, O.; Massaro, A.F.; Drazen, J.M.; Israel, E. Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am. J. Respir. Crit. Care Med., 1998, 157, 769-775.
81. Silkoff, P.E.; Wakita, S.; Chatkin, J.; Ansarin, K.; Gutierrez, C.; Caramori, M.; McClean, P.; Slutsky, A.S.; Zamel, N.; Chapman, K.R. Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. Am. J. Respir. Crit. Care Med., 1999, 159, 940-944.
82. de Gouw, H.W.; Hendriks, J.; Woltman, A.M.; Twiss, I.M.; Sterk, P.J. Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma. Am. J. Respir. Crit. Care Med., 1998, 158, 315-319.
83. Yates, D.H.; Kharitonov, S.A.; Barnes, P.J. Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Eur. Respir. J., 1997, 10, 1483-1488
84. Kharitonov, S.A.; Yates, D.; Barnes, P.J. Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur. Respir. J., 1995, 8, 295-297.
85. de Gouw, H.W.; Grunberg, K.; Schot, R.; Kroes, A.C.; Dick, E.C.; Sterk, P.J. Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects. Eur. Respir. J., 1998, 11, 126-132.
86. van der Mark, T.W.; Kort, E.; Meijer, R.J.; Postma, D.S.; Koeter, G.H. Water vapour and carbon dioxide decrease nitric oxide readings. Eur. Respir. J., 1997, 10, 2120-2123.
87. Silkoff, P.E.; Sylvester, J.T.; Zamel, N.; Permutt, S. Airway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsiveness. Am. J. Respir. Crit. Care Med., 2000, 161, 1218-1228.
88. Tsoukias, N.M.; George, S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J. Appl. Physiol., 1998, 85, 653-666.
89. Malinovschi, A.; Janson, C.; Holmkvist, T.; Norback, D.; Merilainen, P.; Hogman, M. Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur. Respir. J., 2006, 28, 339-345.
90. Yates, D.H.; Breen, H.; Thomas, P.S. Passive smoke inhalation decreases exhaled nitric oxide in normal subjects. Am. J. Respir. Crit. Care Med., 2001, 164, 1043-1046.
91. Warke, T.J.; Mairs, V.; Fitch, P.S.; Ennis, M.; Shields, M.D. Possible association between passive smoking and lower exhaled nitric oxide in asthmatic children. Arch. Environ. Health, 2003, 58, 613-616.
92. Hoyt, J.C.; Robbins, R.A.; Habib, M.; Springall, D.R.; Buttery, L.D.; Polak, J.M.; Barnes, P.J. Cigarette smoke decreases inducible nitric oxide synthase in lung epithelial cells. Exp. Lung Res., 2003, 29, 17-28.
93. Higman, D.J.; Strachan, A.M.; Buttery, L.; Hicks, R.C.; Springall, D.R.; Greenhalgh, R.M.; Powell, J.T. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 546-552.
94. Balint, B.; Donnelly, L.E.; Hanazawa, T.; Kharitonov, S.A.; Barnes, P.J. Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke. Thorax, 2001, 56, 456-461.
95. Wever, R.M.; van Dam, T.; van Rijn, H.J.; de Groot, F.; Rabelink, T.J. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem. Biophys. Res. Commun., 1997, 237, 340-344.
96. Garey, K.W.; Neuhauser, M.M.; Robbins, R.A.; Danziger, L.H.; Rubinstein, I. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest, 2004, 125, 22-26.
97. Therriault, M.J.; Proulx, L.I.; Castonguay, A.; Bissonnette, E.Y. Immunomodulatory effects of the tobacco-specific carcinogen, NNK, on alveolar macrophages. Clin. Exp. Immunol., 2003, 132, 232-238.
98. Jones, J.G.; Minty, B.D.; Lawler, P.; Hulands, G.; Crawley, J.C.; Veall, N. Increased alveolar epithelial permeability in cigarette smokers. Lancet, 1980, 1, 66-68.
99. Berlyne, G.S.; Parameswaran, K.; Kamada, D.; Efthimiadis, A.; Hargreave, F.E. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J. Allergy Clin. Immunol., 2000, 106, 638-644.
100. Jatakanon, A.; Lim, S.; Kharitonov, S.A.; Chung, K.F.; Barnes, P.J. Correlation between exhaled nitric oxide, sputum eosinophils and metacholine responsiveness in patients with mild asthma. Thorax, 1998, 53, 91-95.
101. Brightling, C.E.; Symon, F.A.; Birring, S.S.; Bradding, P.; Wardlaw, A.J.; Pavord, I.D. Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax, 2003, 58, 528-532
102. Smith, A.D.; Cowan, J.O.; Brassett, K.P.; Filsell, S.; McLachlan, C.; Monti-Sheehan, G.; Peter Herbison, G.; Robin Taylor, D. Exhaled nitric oxide: A predictor of steroid response. Am. J. Respir. Crit. Care Med., 2005, 172, 453-459.
103. Maziak, W.; Loukides, S.; Culpitt, S.; Sullivan, P.; Kharitonov, S.A.; Barnes, P.J. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1998, 157, 998-1002.
104. Rutgers, S.R.; van der Mark, T.W.; Coers, W.; Moshage, H.; Timens, W.; Kauffman, HF.; Koëter, G.H.; Postma, D.S. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax, 1999, 54, 576-580.
105. Pedoto, A.; Caruso, J.E.; Nandi, J.; Oler, A.; Hoffmann, S.P.; Tassiopoulos, A.K.; McGraw, D.J.; Camporesi, E.M.; Hakim, T.S. Acidosis stimulates nitric oxide production and lung damage in rats. Am. J. Respir. Crit. Care Med., 1999, 159, 397-402.
106. Brindicci, C.; Ito, K.; Resta, O.; Pride, N.B.; Barnes, P.J.; Kharitonov, S.A. Exhaled nitric oxide from lung periphery is increased in COPD. Eur. Respir. J., 2005, 26, 52-9.
107. Montuschi, P.; Kharitonov, S.A.; Barnes, P.J. Exhaled carbon monoxide and nitric oxide in COPD. Chest, 200, 120(2), 496-501.
108. Di Stefano, A.; Caramori, G.; Oates, T.; Capelli, A.; Lusuardi, M.; Gnemmi, I.; Ioli, F.; Chung, K.F.; Donner, C.F.; Barnes, P.J.; Adcock, I.M. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J., 2002, 20, 556-63.
109. Agusti, A.; Morla, M.; Sauleda, J.; Saus, C.; Busquets, X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax, 2004, 59, 483-7
110. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J., 2000, 357, 593-615.
111. Yates, D.H.; Kharitonov, S.A.; Thomas, P.S.; Barnes, P.J. Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. Am. J. Respir. Crit. Care Med., 1996, 154, 247-50.
112. Gomez, FP.; Barbera, J.A.; Roca, J.; Iglesia, R.; Ribas, J.; Barnes, P.J.; Rodriguez-Roisin, R. Effect of nitric oxide synthesis inhibition with nebulized L-NAME on ventilation-perfusion distributions in bronchial asthma. Eur. Respir. J., 1998, 12, 865-71.
113. Yates, D.H.; Kharitonov, S.A.; Robbins, R.A.; Thomas, P.S.; Barnes, P.J. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am. J. Respir. Crit. Care Med., 1995, 152, 892-6.
114. Brindicci, C.; Ito, K.; Barnes, P.J.; Kharitonov, S.A. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest, 2007, 131, 1353-62.
115. Maestrelli, P.; Paska, C.; Saetta, M.; Turato, G.; Nowicki, Y.; Monti, S.; Formichi, B.; Miniati, M.; Fabbri, L.M. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur. Respir. J., 2003, 21, 971-6.
116. Brindicci, C.; Kharitonov, S.A.; Barnes, P.J.; Ito K. Expression of Nitric Oxide Synthase in Peripheral Lungs of COPD Patients. Am. J. Respir. Crit. Care Med., 2005, Suppl. 2, A930.
117. Kharitonov, S.A.; Yates, D.; Robbins, R.A.; Logan-Sinclair, R.; Shinebourne, E.A.; Barnes, P.J. Increased nitric oxide in exhaled air of asthmatic patients. Lancet, 1994, 343, 133-135
118. Kharitonov, S.A.; Yates, D.H.; Barnes, P.J. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am. J. Respir. Crit. Care Med., 1996, 153, 454-457.
119. Robbins, R.A.; Barnes, P.J.; Springall, D.R.; Warren, J.B.; Kwon, O.J.; Buttery, L.D.; Wilson, A.J.; Geller, D.A.; Polak, J.M. Expression of inducible nitric oxide in human lung epithelial cells. Biochem. Biophys. Res. Commun., 1994, 203, 209-218.
120. Ferreira, I.M.; Hazari, M.S.; Gutierrez, C.; Zamel, N.; Chapman, K.R. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: Effects of inhaled beclomethasone. Am. J. Respir. Crit. Care Med., 2001, 164, 1012-1015.
121. Papi, A.; Romagnoli, M.; Baraldo, S.; Braccioni, F.; Guzzinati, I.; Saetta, M.; Ciaccia, A.; Fabbri, L. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2000, 162, 1773-1777.
122. Liu, J.; Sandrini, A.; Thurston, M.C.; Yates, D.H.; Thomas, P.S. Nitric oxide and exhaled nitrite/nitrates in Chronic Obstructive Pulmonary Disease patients. Respiration, 2007, 74, 617-623
123. Barnes, P.J.; Adcock, I.M.; Ito, K. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur. Respir. J., 2005, 25, 552-563.
124. Kharitonov, S.A.; Barnes, P.J. Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Curr. Allergy Asthma Rep., 2003, 3, 121-129.
125. van Straaten, J.F.; Postma, D.S.; Coers, W.; Noordhoek, J.A.; Kauffman, H.F.; Timens, W. Macrophages in lung tissue from patients with pulmonary emphysema express both inducible and endothelial nitric oxide synthase. Mod. Pathol., 1998, 11, 648-655.
126. Vass, G.; Huszar, E.; Barat, E.; Valyon, M.; Kiss D.; Penzes, I.; Augusztinovicz, M.; Horvath, I. Comparison of nasal and oral inhalation during exhaled breath condensate collection. Am. J. Respir. Crit. Care Med., 2003, 167, 850-55.
127. Sznajder, J.I.; Fraiman, A.; Hall, J.B.; Sanders, W.; Schmidt, G.; Crawford, G.; Nahum, A.; Factor, P.; Wood, L.D. Increased hydrogen peroxide in the expired breath of patients with acute hypoxemic respiratory failure. Chest, 1989, 96, 606-12.
128. Jackson, A.S.; Sandrini, A.; Campbell, C.; Chow, S.; Thomas, P.S.; Yates, D.H. Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am. J. Respir. Crit. Care Med., 2007, 175, 222-27.
129. Borrill, Z.L.; Roy, K.; Singh, D. Exhaled breath condensate biomarkers in COPD. Eur. Respir. J., 2008, 32, 472-86.
130. Vogelberg, C.; Hirsch, T.; Rosen-Wolff, A.; Kerkmann, M.L.; Leupold, W. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis. Pediatr. Pulmonol., 2003, 36, 348-52.
131. Kostikas, K.; Papatheodorou, G.; Psathakis, K.; Panagou, P.; Loukides, S. Oxidative stress in expired breath condensate of patients with COPD. Chest, 2003, 124, 1373-80.
132. Ganas, K.; Loukides, S.; Papatheodorou, G.; Panagou, P.; Kalogeropoulos, N. Total nitrite/nitrate in expired breath condensate of patients with asthma. Respir. Med., 2001, 95, 649-54.
133. van Beurden, WJ.; Harff, G.A.; Dekhuijzen, P.N.R.; van den Bosch, M.J.; Creemers, J.P.; Smeenk, F.W. An efficient and reproducible method for measuring hydrogen peroxide in exhaled breath condensate. Respir. Med., 2002, 96, 197-03.
134. Prieto, L.; Ferrer, A.; Palop, J.; Domenech, J.; Llusar, R.; Rojas, R. Differences in exhaled breath condensate pH measurements between samples obtained with two commercial devices. Respir. Med., 2007, 101, 1715-20.
135. Kostikas, K.; Gaga, M.; Papatheodorou, G.; Karamanis, T.; Orphanidou, D.; Loukides, S. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest, 2005, 127, 1553-59.
136. Borrill, Z.L.; Starkey, R.C.; Singh, S.D. Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis., 2007, 2, 71-6.
137. Loukides, S.; Bouros, D.; Papatheodorou, G.; Panagou, P.; Siafakas, N.M. The relationships among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. Chest., 2002, 121, 338-46.
138. Biernacki, W.A.; Kharitonov, S.A.; Barnes, P.J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax, 2003, 58, 294-98
139. Montuschi, P.; Barnes, P.J. Exhaled leukotrienes and prostaglandins in asthma. J. Allergy. Clin. Immunol., 2002, 109, 615-20.
140. Effros, R.M.; Biller, J.; Foss, B.; Hoagland, K.; Dunning, M.B.; Castillo, D.; Bosbous, M.; Sun, F.; Shaker, R. A simple method for estimating respiratory solute dilution in exhaled breath condensates. Am. J. Respir. Crit. Care Med., 2003, 168, 1500-05
141. Montuschi, P.; Ragazzoni, E.; Valente, S.; Corbo, G.; Mondino, C.; Ciappi, G.; Ciabattoni, G. Validation of 8-isoprostane and prostaglandin E(2) measurements in exhaled breath condensate. Inflamm. Res., 2003, 52, 502-07.
142. Montuschi, P.; Ragazzoni, E.; Valente, S.; Corbo, G.; Mondino, C.; Ciappi, G.; Barnes, P.J.; Ciabattoni, G. Validation of leukotriene B4 measurements in exhaled breath condensate. Inflamm. Res., 2003, 52, 69-73.
143. Barnes, P.J. Reactive oxygen species and airway inflammation. Free Radic. Biol. Med., 1990, 9, 235-43.
144. Gallati, H.; Pracht, I. Horseradish peroxidase: Kinetic studies and optimization of peroxidase activity determination using the substrates H2O2 and 3,3',5,5'-tetramethylbenzidine. J. Clin. Chem. Clin. Biochem., 1985, 23, 453-60.
145. Dekhuijzen, P.N.; Aben, K.K.; Dekker, I.; Aarts, L.P.; Wielders, P.L.; van Herwaarden, C.L.; Bast, A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1996, 154, 813-16.
146. Hyslop, P.A.; Sklar, L.A. A quantitative fluorimetric assay for the determination of oxidant production by polymorphonuclear leukocytes: Its use in the simultaneous fluorimetric assay of cellular activation processes. Anal. Biochem., 1984, 141, 280-86.
147. 2 production by macrophages and neutrophils with homovanillic acid and horseradish peroxidase. J. Immunol. Methods, 1983, 63, 347-57.
148. 2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic. Biol. Med., 2001, 30, 178-86.
149. Gerritsen, W.B.; Zanen, P.; Bauwens, A.A.; van den Bosch, J.M.; Haas, F.J. Validation of a new method to measure hydrogen peroxide in exhaled breath condensate. Respir. Med., 2005, 99, 1132-37.
150. Nowak, D.; Kasielski, M.; Antczak, A.; Pietras, T.; Bialasiewicz, P.; Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: No significant effect of cigarette smoking. Respir. Med., 1999, 93, 389-396
151. Gerritsen, W.B.; Asin, J.; Zanen, P.; van den Bosch, J.M.; Haas, F.J.
152. van Beurden, W.J.; Harff, GA.; Dekhuijzen, P.N.; van der Poel-Smet, S.M.; Smeenk, F.W. Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration, 2003, 70, 242-48.
153. Kasielski, M.; Nowak, D. Long-term administration of Nacetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir. Med., 2001, 95, 448-56.
154. Montuschi, P.; Barnes, P.J.; Roberts L.J. 2nd. Insights into oxidative stress: The isoprostanes. Curr. Med. Chem., 2007, 14, 703-717.
155. Montuschi, P.; Barnes, P.J.; Roberts, L.J, 2nd. Isoprostanes: Markers and mediators of oxidative stress. FASEB J., 2004, 18, 1791-1800.
156. Montuschi, P.; Collins, J.V.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S.A.; Barnes, P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 2000, 62, 1175-77.
157. Ko, F.W.; Lau, C.Y.; Leung, T.F.; Wong, G.W.; Lam, C.W.; Hui, D.S. Exhaled breath condensate levels of 8-isoprostane, growth related oncogene α and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir. Med., 2006, 100, 630-38.
158. van Hoydonck, P.G.; Wuyts, W.A.; Vanaudenaerde, B.M.; Schouten, E.G.; Dupont, L.J.; Temme, E.H. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. Eur. Respir. J., 2004, 23, 189-192.
159. Liebler, D.C.; Reed, D.J. Free-radical defence and repair mechanisms. In: Wallance KB, editor. Free radical toxicology. New York: Publisher Press, 1999, 141-71.
160. Esterbauer, H.; Schaur, R.J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med., 1991, 11, 81-28.
161. Pryor, W.A.; Das, B.; Church, D.F. The ozonation of unsaturated fatty acids: Aldehydes and hydrogen peroxide as products and possible mediators of ozone toxicity. Chem. Res. Toxicol., 1991, 4, 341-48.
162. Gelpi, E. Biomedical and biochemical applications of liquid chromatography-mass spectrometry. J. Chromatogr. A., 1995, 703, 59-80.
163. Corradi, M.; Rubinstein, I.; Andreoli, R.; Mannini, P.; Caqlieri, A.; Poli, D.; Alinovi, R.; Muttiu, A. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2003, 167, 1380-86.
164. Ricciardolo, F.L.; Di Stefano, A.; Sabatini, F.; Folkerts, G. Reactive nitrogen species in the respiratory tract. Eur. J. Pharmacol., 2006, 533, 240-52.
165. Green, L.C.; Wagner, D.A.; Glogowski, J.; Skipper, P.L.; Wishnok, J.S.; Tannen-baum, S.R. Analysis of nitrate nitrite and [15N] nitrate in biological fluids. Anal. Biochem., 1982, 126, 131-38.
166. Moshage, H.; Kok, B.; Huizeng, R.; Jansen, P. Nitrate and nitrite determination in plasma. A critical evaluation. Clin. Chem., 1995, 41, 892-96.
167. Corradi, M.; Pesci, A.; Casana, R.; Alinovi, R.; Goldoni, M.; Vettori, M,V.; Cuomo, A.. Nitrate in exhaled breath condensate of patients with different airway diseases. Nitric. Oxide, 2003, 8, 26-30.
168. Park, J.K.; Kostka, P. Fluorometric detection of biological S-nitrosothiols. Anal. Biochem., 1997, 249, 61-6
169. Tsikas, D.; Fuchs, I.; Gutzki, F.M.; Frolich, J.C. Measurement of nitrite and nitrate in plasma, serum and urine of humans by high-performance liquid chromatography, the Griess assay, chemiluminescence and gas chromatography-mass spectrometry: interferences by biogenic amines and N(G)-nitro-L-arginine analogs. J. Chromatogr. B. Biomed. Sci., 1998, 715, 441-44.
170. Corradi, M.; Montuschi, P.; Donnelly, L.E.; Pesci, A.; Kharitonov, S.A.; Barnes, P.J. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am. J. Respir. Crit. Care Med., 2001, 163, 854-58.
171. Carpagnano, G.E.; Foschino Barbaro, M.P.; Cagnazzo, M; Di Gioia, G.; Giliberti, T.; Di Matteo, C.; Resta, O. Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge. Chest, 2005, 128, 3159-66.
172. Carpagnano, GE.; Kharitonov, S.A.; Foschino-Barbaro, M.P.; Resta, O.; Gramiccioni, E.; Barnes, P.J. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur. Respir. J., 2003, 21, 589-93.
173. Sack, U.; Scheibe, R.; Wötzel, M.; Hammerschmidt, S.; Kuhn, H.; Emmrich, F.; Hoheisel, G.; Wirtz, H.; Gessner, C. Multiplex analysis of cytokines in exhaled breath condensate. Cytometry, 2006, 69, 169-72.
174. Gessner, C.; Scheibe, R.; Wötzel, M.; Hammerschmidt, S.; Kuhn, H.; Engelmann, L.; Hoheisel, G.; Gillissen, A.; Sack, U.; Wirtz, H. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir. Med., 2005, 99, 1229-40.
175. Balbi, B. COPD: Is chemotaxis the key? Chest, 2003, 123, 983-86.
176. Montuschi, P.; Kharitonov, S.A.; Ciabattoni, G.; Barnes, P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax, 2003, 58, 585-88.
177. Montuschi, P.; Macagno, F.; Parente, P.; Valente, S.; Lauriola, L.; Ciappi, G.; Kharitonov, S.A.; Barnes, P.J.; Ciabattoni, G. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax, 2005, 60, 827-33.
178. Kostikas, K.; Papatheodorou, G.; Ganas, K.; Psathakis, K.; Panagou, P.; Loukides, S. pH in expired breath condensate of patients with inflammatory airway diseases. Am. J. Respir. Crit. Care Med., 2002, 165, 1364-70.
179. Vaughan, J.; Ngamtrakulpanit, L.; Pajewski, T.N.; Turner, R.; Nguyen, T.A.; Smith, A.; Urban, P.; Hom, S.; Gaston, B.; Hunt, J. Exhaled breath condensate pH is a robust and reproducible assay of airway acidity. Eur. Respir. J., 2003, 22, 889-94.
180. Paget-Brown, A.O.; Ngamtrakulpanit, L.; Smith, A.; Bunyan, D.; Hom, S.; Nguyen, A.; Hunt, J.F. Normative data for pH of exhaled breath condensate. Chest, 2006, 129, 426-30.
181. Kullmann, T.; Barta, I.; Lazar, Z.; Szili, B.; Barat, E.; Valyon, M.; Kollai, M.; Horvath, I. Exhaled breath condensate pH standardised for CO2 partial pressure. Eur. Respir. J., 2007, 29, 496-01.
182. Effros, R.M.; Casaburi, R.; Su, J.; Dunning, M.; Torday, J.; Biller, J.; Shaker, R. The effects of volatile salivary acids and bases on exhaled breath condensate pH. Am. J. Respir. Crit. Care Med., 2006, 173, 386-92.
183. Wells, K.; Vaughan, J.; Pajewski, T.N.; Hom, S.; Ngamtrakulpanit, L.; Smith, A.; Nguyen, A.; Turner, R.; Hunt, J. Exhaled breath condensate pH assays are not influenced by oral ammonia. Thorax, 2005, 60, 27-31.
184. Leung, T.F.; Li, C.Y.; Yung, E.; Liu, E.K.; Lam, C.W.; Wong, G.W. Clinical and technical factors affecting pH and other biomarkers in exhaled breath condensate. Pediatr. Pulmonol., 2006, 41, 87-94.
185. Borrill, Z.; Starkey, C.; Vestbo, J.; Singh, D. Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. Eur. Respir. J., 2005, 25, 269-74.
186. Paredi, P.; Kharitonov, S.A.; Leak, D.; Ward, S.; Cramer, D.; Barnes, P.J. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2000, 162, 369-73.
187. Habib, M.P.; Tank, L.J.; Lane, L.C.; Garewal, H.S. Effect of vitamin E on exhaled ethane in cigarette smokers. Chest, 1999, 115, 684-690.
188. Scott, S.M.; James, D.; Ali, Z. Data analysis for electronic nose systems. Microchem Acta, 2007, 156, 183-207.
189. Briglin, S.M.; Freund, M.S.; Tokumaru, P.; Lewis, N.S. Exploitation of spatio-temporal information and geometric optimization of signal nose performance using arrays of carbon black-polymer composite vapour detectors. Sens Actuators B, 2002, 82, 54-74.
190. Dragonieri, S.; Annema, J.T.; Schot, R.; van der Schee, M.P.C.; Spanevello, A.; Carrati, P.; Resta, O.; Rabe, K.F.; Sterk, P.J. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer, 2009, 64, 166-170.